Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE in Adults Aged 65 Years and Older
Moderna (MRNA) published a study in JAMA Network Open showing mNEXSPIKE's effectiveness against COVID-19 in adults 65+ compared to Comirnaty. The study found 35.9% relative effectiveness against medically attended COVID-19 and 47.0% against hospitalization. The analysis included 294,499 U.S. veterans.
How this was made
The 30-second read
Why it matters
The study provides the first real‑world comparative effectiveness evidence, potentially influencing investor sentiment and vaccine market dynamics.
Market read
New efficacy data may boost Moderna's vaccine portfolio valuation and affect related biotech stocks.
What to watch
Regulatory approvals, pricing negotiations, and potential safety concerns could temper impact.
Background
Moderna's mNEXSPIKE is a booster vaccine targeting older adults; the study compares it to Pfizer's Comirnaty using U.S. Veterans data.
Ticker impact
Moderna announced publication of a large real‑world study showing its mNEXSPIKE vaccine outperforms Pfizer's Comirnaty in older adults.
potential modest upside as investors price in stronger vaccine efficacy
First‑time disclosure of statistically significant efficacy advantage; large sample size adds credibility.
Market effects
strengthens outlook for mRNA vaccine and broader biotech sector
U.S. market focus
moderate, as vaccine efficacy data is globally relevant
Counterpoint
Efficacy advantage may not translate into higher sales if uptake remains limited or competition intensifies.
Key entities
- CompanyModerna, Inc.
Developer of the mNEXSPIKE COVID‑19 vaccine.
- CompanyPfizer/BioNTech (Comirnaty)
Competing mRNA COVID‑19 vaccine used as comparator.
